alt

7th International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention (IAS 2013)

June 30-July 3, 2013, Kuala Lumpur

IAS 2013: HIV May Be Present in Semen Despite Undetectable Blood Viral Load

Gay men with HIV can shed the virus in their semen even when they are on antiretroviral therapy (ART) with fully suppressed blood plasma viral load, according to a longitudinal French study presented at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

Read more:

IAS 2013: Lower-dose Lopinavir/Ritonavir Reduces Side Effects, Maintains Viral Control in HIV+ Children

Low dose lopinavir/ritonavir (Kaletra or Aluvia) -- 70% of the standard dose -- worked as well as the standard dose in maintaining viral suppression, but with less dyslipidemia, among children with HIV in Thailand, Thanyawee Puthanakit reported on behalf of the HIVNAT 152 PEARL study at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

Read more:

IAS 2013: Strategies to Detect and Treat Gay Men with Acute HIV Infection

The detection and control of acute (very recent) HIV infection may be a powerful HIV prevention measure for epidemics in men who have sex with men (MSM), Eugène Kroon of the Thai Red Cross AIDS Research Center reported at a late-breaker session at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur. Immediate HIV treatment was associated with rapid falls in viral load and sustained behavior change.

alt

Read more:

IAS 2013: People with HIV Who Use Statins May Have Lower Cancer Risk

HIV positive people who use statins to manage high cholesterol also may reduce their risk of developing non-AIDS-defining malignancies, according to study findings reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

Read more:

IAS 2013: Women Who Start Option B+ ART During Pregnancy Often Lost to Follow-up

Women who begin HIV treatment during pregnancy or while breastfeeding, prior to the CD4 cell threshold previously recommended for starting treatment (350 cells/mm3), were significantly more likely to be lost to follow-up than women who started treatment at the general treatment threshold, Malawian researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur.

alt

Read more: